TY  - BOOK
AU  - Ben-Dor, Itsik
AU  - Didier, Romain
AU  - Kiramijyan, Starkis
AU  - Koifman, Edward
AU  - Kumar, Sandeep
AU  - Patel, Nirav
AU  - Pichard, Augusto D
AU  - Satler, Lowell F
AU  - Tavil-Shatelyan, Arpi J
AU  - Torguson, Rebecca
AU  - Waksman, Ron
AU  - Weissman, Gaby
TI  - Outcome of implantation of a second self-expanding valve for the treatment of residual significant aortic regurgitation
SN  - 1522-1946
PY  - 2017///
KW  - *Aortic Valve Insufficiency/su [Surgery]
KW  - *Aortic Valve Stenosis/su [Surgery]
KW  - *Aortic Valve/su [Surgery]
KW  - *Heart Valve Prosthesis
KW  - *Transcatheter Aortic Valve Replacement/is [Instrumentation]
KW  - Aged
KW  - Aged, 80 and over
KW  - Aortic Valve Insufficiency/dg [Diagnostic Imaging]
KW  - Aortic Valve Insufficiency/et [Etiology]
KW  - Aortic Valve Insufficiency/pp [Physiopathology]
KW  - Aortic Valve Stenosis/dg [Diagnostic Imaging]
KW  - Aortic Valve Stenosis/pp [Physiopathology]
KW  - Aortic Valve/dg [Diagnostic Imaging]
KW  - Aortic Valve/pp [Physiopathology]
KW  - Female
KW  - Hemodynamics
KW  - Humans
KW  - Male
KW  - Prosthesis Design
KW  - Risk Factors
KW  - Time Factors
KW  - Transcatheter Aortic Valve Replacement/ae [Adverse Effects]
KW  - Treatment Outcome
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
N1  - Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006
N2  - BACKGROUND: Residual aortic regurgitation (AR) following transcatheter aortic valve replacement (TAVR) is associated with adverse outcome. We sought to evaluate the efficacy and safety of second CoreValve (CV) implantation to treat residual AR following the initial CV deployment; CONCLUSIONS: Second implantation of self-expanding valve can successfully reduce residual significant AR following initial CV implantation and should be considered as therapeutic option for this population. � 2017 Wiley Periodicals, Inc; Copyright � 2017 Wiley Periodicals, Inc; METHODS AND RESULTS: TAVR patients treated with a second CV due to moderate and above residual AR were compared to single device implantation. Valvular function parameters were compared at baseline, post procedure, and 30 days. Among 172 CV TAVR patients, 11 required a second device (6%) due to significant residual AR. The main differences between the groups were higher rates of low ejection fraction in patients with 2 CV implanted and higher annular diameter (27 [29-25] vs. 25 [26-24] mm, P=0.03), requiring a larger device. Although two patients in the two CV group had high initial implantation, low implantation was similar between the groups. A second CV achieved adequate reduction in residual AR in six patients (55%), while an additional four patients had moderate residual AR. Only one remained with moderate to severe AR after 30 days follow-up. There were no cases of peri-procedural stroke or mortality
UR  - https://dx.doi.org/10.1002/ccd.26960
ER  -